The Diagnostic Journey: Connecting the Dots
At a Glance
RRMS is diagnosed by combining symptoms and a neurological examination with MRI and, when needed, spinal-fluid or blood tests. Doctors look for MS-related changes in different parts of the brain, spinal cord, or optic nerves and at different times while ruling out similar conditions.
Getting a diagnosis for RRMS is a process of “connecting the dots” while simultaneously “ruling everything else out.” Because there is no single blood test that says “yes” or “no” to MS, doctors use a set of international standards called the McDonald Criteria to ensure the diagnosis is accurate and timely [1].
The Rule of Space and Time
To be diagnosed with MS, your medical team must find evidence that the disease has occurred in different parts of your central nervous system (CNS) and at different points in time. This is known as Dissemination in Space (DIS) and Dissemination in Time (DIT) [1][2]. Always, diagnosis requires clinical judgment and the exclusion of better explanations.
Dissemination in Space (DIS)
Doctors look for characteristic MS lesions in specific areas of the brain and spinal cord. Under the most recent 2024 updates, there are now five key regions where these lesions typically appear (usually lesions in at least two regions are required):
- Periventricular: Areas immediately surrounding the fluid-filled spaces (ventricles) in the brain [3].
- Cortical/Juxtacortical: Lesions located in or right next to the brain’s outer “gray matter” layer [3][4].
- Infratentorial: The lower parts of the brain, including the brainstem and cerebellum [3].
- Spinal Cord: Lesions found anywhere along the length of the spine [3].
- Optic Nerve: Evidence of inflammation in the nerves connecting your eyes to your brain [2][5].
Dissemination in Time (DIT)
This proves the immune activity is an ongoing process, not just a one-time event. DIT can be confirmed if:
- Your MRI shows both “active” (enhancing with contrast) and “old” (non-enhancing) lesions at the same time [6].
- A follow-up MRI shows a brand-new lesion that wasn’t there before [6].
- Oligoclonal Bands (OCBs): If your spinal fluid shows these specific proteins, they can serve as a substitute for “time,” allowing for an earlier diagnosis even if only one “event” has occurred [1][6]. Under newer guidelines, the kappa free-light chain index is an alternative CSF marker, and in some highly specific presentations, DIT may not be separately required.
What the Doctor Sees on Your MRI
Radiologists may look for very specific “signatures” that help distinguish MS from other conditions like migraine or aging-related changes. Keep in mind, these are advanced markers and not having them does not rule out an MS diagnosis:
- Dawson’s Fingers: These are oval-shaped lesions that stick out from the brain’s ventricles like fingers. They follow the path of small veins and are highly characteristic of MS [7].
- Central Vein Sign (CVS): Using specialized MRI scans, doctors can see a tiny vein running through the center of an MS lesion. If a high percentage of your lesions have this “central vein,” it strongly points toward MS rather than a mimic [8][9].
- Paramagnetic Rim Lesions (PRLs): These are “smoldering” lesions with a dark rim of iron at the edge. They are highly specific to MS and suggest chronic, active inflammation [10][11].
Ruling Out the Mimics
Before confirming MS, your doctor must ensure your symptoms aren’t caused by “mimics”—other autoimmune diseases that look like MS but require different treatments. Two of the most common are:
- NMOSD (Neuromyelitis Optica): Often involves severe vision loss in both eyes or long lesions in the spinal cord. It is evaluated using the AQP4 antibody blood test [12][13].
- MOGAD (MOG-Antibody Disease): Can look like MS but often has different MRI patterns and recovery styles. It is evaluated using the MOG antibody blood test [14][15].
A negative antibody test does not completely exclude these conditions; results are interpreted alongside clinical and MRI patterns. An isolated episode of optic neuritis (vision loss) or myelitis (spinal cord inflammation) is called a Clinically Isolated Syndrome (CIS). While it can be the first sign of MS, it is not an automatic diagnosis unless the “Space and Time” criteria above are also met [1].
Tests That May Be Considered
To ensure your diagnosis is thorough and accurate, your medical records should ideally include some combination of the following, tailored to your case:
| Test Category | What is it looking for? |
|---|---|
| Brain MRI | Typical lesion distribution (e.g., Dawson’s fingers, CVS) [7][8]. |
| Spine MRI | Lesions in the cervical (neck) or thoracic (mid-back) cord [3]. |
| Contrast (Gadolinium) | Distinguishes between active inflammation and older damage [6]. |
| Lumbar Puncture | Checks for Oligoclonal Bands or the Kappa Free-Light Chain Index [1][16]. |
| Blood Work | Help evaluate for NMOSD (AQP4-IgG) and MOGAD (MOG-IgG) [12][14]. |
| Neurological Exam | Clinical evidence of vision, strength, or balance changes [1]. |
If any of these pieces are missing, it may be worth asking your neurologist if they are necessary to confirm your specific case.
Common questions in this guide
How is RRMS diagnosed if there is no single MS blood test?
What do dissemination in space and dissemination in time mean in MS?
Can oligoclonal bands or a kappa free-light chain index help diagnose RRMS?
What MRI findings can support an MS diagnosis?
Why are AQP4 and MOG antibody tests used when MS is suspected?
Is clinically isolated syndrome the same as multiple sclerosis?
One line in your results can change your plan.
A negative AQP4 or MOG antibody test does not completely exclude NMOSD or MOGAD, which require different treatments. We check your results against the latest research to help you prepare for what’s next.
Related questions
Get notified when new evidence is published on relapsing-remitting multiple sclerosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (16)
- 1
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
Thompson AJ, Banwell BL, Barkhof F, et al.
The Lancet. Neurology 2018; (17(2)):162-173 doi:10.1016/S1474-4422(17)30470-2.
PMID: 29275977 - 2
Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria.
Montalban X, Lebrun-Frénay C, Oh J, et al.
The Lancet. Neurology 2025; (24(10)):850-865 doi:10.1016/S1474-4422(25)00270-4.
PMID: 40975101 - 3
Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017 - continuity and change.
Hartung HP, Graf J, Aktas O, et al.
Current opinion in neurology 2019; (32(3)):327-337 doi:10.1097/WCO.0000000000000699.
PMID: 30985371 - 4
Lesion topographies in multiple sclerosis diagnosis: A reappraisal.
Arrambide G, Tintore M, Auger C, et al.
Neurology 2017; (89(23)):2351-2356 doi:10.1212/WNL.0000000000004715.
PMID: 29101276 - 5
The use of optical coherence tomography and visual evoked potentials in the 2024 McDonald diagnostic criteria for multiple sclerosis.
Saidha S, Green AJ, Leocani L, et al.
The Lancet. Neurology 2025; (24(10)):880-892 doi:10.1016/S1474-4422(25)00275-3.
PMID: 40975103 - 6
Investigating Whether Dissemination in Time Is Essential to Diagnose Relapsing Multiple Sclerosis.
Brownlee WJ, Foster MA, Pontillo G, et al.
Neurology 2025; (104(7)):e210274 doi:10.1212/WNL.0000000000210274.
PMID: 40036713 - 7
Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis.
Jurynczyk M, Geraldes R, Probert F, et al.
Brain : a journal of neurology 2017; (140(3)):617-627 doi:10.1093/brain/aww350.
PMID: 28364548 - 8
Central vein sign: A putative diagnostic marker for multiple sclerosis.
Chaaban L, Safwan N, Moussa H, et al.
Acta neurologica Scandinavica 2022; (145(3)):279-287 doi:10.1111/ane.13553.
PMID: 34796472 - 9
Updated French OFSEP recommendations for multiple sclerosis MRI: alignment with the 2024 McDonald criteria.
Lecler A, Mondot L, Homo C, et al.
Journal of neuroradiology = Journal de neuroradiologie 2026; (53(5)):101576 doi:10.1016/j.neurad.2026.101576.
PMID: 42250869 - 10
Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis.
Meaton I, Altokhis A, Allen CM, et al.
Multiple sclerosis (Houndmills, Basingstoke, England) 2022; (28(14)):2212-2220 doi:10.1177/13524585221118677.
PMID: 36017870 - 11
Central vein sign and paramagnetic rim lesion abbreviated counting methods for diagnosis of multiple sclerosis: a systematic review and meta-analysis.
Toljan K, Amin M, Ontaneda D
Clinical radiology 2025; (88()):106984 doi:10.1016/j.crad.2025.106984.
PMID: 40716383 - 12
Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria.
Banwell B, Bennett JL, Marignier R, et al.
The Lancet. Neurology 2023; (22(3)):268-282 doi:10.1016/S1474-4422(22)00431-8.
PMID: 36706773 - 13
Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein IgG associated disorder: A comprehensive neuro-ophthalmic review.
Sharma J, Bhatti MT, Danesh-Meyer HV
Clinical & experimental ophthalmology 2021; (49(2)):186-202 doi:10.1111/ceo.13863.
PMID: 33426799 - 14
Use of Fluid Biomarkers in NMOSD and MOGAD: Clinical and Research Applications.
Mariotto S, Cobo-Calvo A, Khalil M, et al.
Neurology(R) neuroimmunology & neuroinflammation 2026; (13(5)):e200627 doi:10.1212/NXI.0000000000200627.
PMID: 42579841 - 15
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
Flanagan EP, Hemingway C
Continuum (Minneapolis, Minn.) 2026; (32(2)):481-512 doi:10.1212/cont.0000000000001678.
PMID: 41925507 - 16
Positive cerebrospinal fluid in the 2024 McDonald criteria for multiple sclerosis.
Deisenhammer F, Hegen H, Arrambide G, et al.
EBioMedicine 2025; (120()):105905 doi:10.1016/j.ebiom.2025.105905.
PMID: 40967951
This page is for informational purposes only and does not constitute medical advice or diagnose RRMS. Your neurologist should interpret your MRI, spinal-fluid, blood-test, and examination results in the context of your symptoms.